Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
88.19
+0.96 (+1.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
442,313
Open
88.31
Bid (Size)
87.80 (1)
Ask (Size)
88.91 (2)
Prev. Close
87.23
Today's Range
87.76 - 89.68
52wk Range
76.53 - 125.83
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
August 22, 2024
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to...
Via
Benzinga
Exposures
COVID-19
Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
Pfizer Inc.
Via
Business Wire
Performance
YTD
-21.50%
-21.50%
1 Month
+6.07%
+6.07%
3 Month
-9.04%
-9.04%
6 Month
-6.15%
-6.15%
1 Year
-25.92%
-25.92%
More News
Read More
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Unveiling 12 Analyst Insights On BioNTech
August 19, 2024
Via
Benzinga
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
August 19, 2024
Via
Benzinga
Topics
ETFs
Exposures
COVID-19
Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Via
MarketBeat
Exposures
COVID-19
Product Safety
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
August 19, 2024
Via
Benzinga
Exposures
Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
August 19, 2024
Via
The Motley Fool
Why Pfizer Stock Slumped on Friday
August 16, 2024
Via
The Motley Fool
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
August 16, 2024
Via
Investor's Business Daily
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
August 16, 2024
Via
Benzinga
Exposures
COVID-19
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
BioNTech SE
Via
GlobeNewswire
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
August 13, 2024
Via
Benzinga
Exposures
COVID-19
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
August 13, 2024
Via
Benzinga
Exposures
COVID-19
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
August 12, 2024
Via
MarketBeat
Exposures
COVID-19
3 Biotech Stocks With Promising Drug Pipelines: August 2024
August 08, 2024
Via
InvestorPlace
Exposures
Product Safety
This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
August 07, 2024
Via
Benzinga
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
August 05, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets Monday?
August 05, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
August 05, 2024
Via
Investor's Business Daily
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q2 2024
August 05, 2024
Via
InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
August 05, 2024
Via
Benzinga
Exposures
COVID-19
Nasdaq, R2K Futures Tumble Over 4%, VIX Spikes Over 100%, Bitcoin Plunges Hard As Global Sell-Off Deepens Amid Recession Fears
August 05, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
August 05, 2024
From
BioNTech SE
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.